David A. Sallman – författare
Visar alla böcker från författaren David A. Sallman. Handla med fri frakt och snabb leverans.
2 produkter
2 produkter
Häftad, Engelska, 2020
1 392 kr
Skickas inom 3-6 vardagar
This revised and updated second edition of Handbook of Hematologic Malignancies continues to be an essential and "go-to" resource for the busy hematologist, hematologic oncologist, hematopathologist, oncology advanced practice provider, oncology nurse, and trainee. Concisely organized, each chapter provides the most current, need-to-know points of diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematological malignancy. Chapters are complete with richly illustrated figures to highlight the hematopathologic characteristics of diseases in addition to helpful tables on differential diagnosis, prognostic scoring systems, molecular profiles, and therapeutic options. A new case-based chapter concludes the handbook with clinical cases designed to test a clinician's knowledge of pathologic diagnosis and clinical presentation of diseases covered in the book. With over twenty new FDA-approved indications since publication of the first edition, including breakthroughs with CAR-T therapy, and other evidence-based treatment options for patients with hematologic disease, this book serves as quick reference to practice changing information on challenging diagnostic dilemmas, frontline and refractory treatment scenarios, and more.The subspecialty field of hematologic oncology is ever-changing and expanding with available treatment options and this second edition keeps the busy clinician abreast of recent findings and their impact on evidence-based treatment and management. Written by experienced clinicians at the world-renowned Moffitt Cancer Center in Tampa, Florida, as well as contributions from leading academicians, hematologists, and oncologists throughout the country, this unique handbook is packed with authoritative knowledge and clinical insight into all known hematologic cancers.Key Features:Includes seven new chapters covering CAR-T and novel therapeutic options including CD19 CAR-T therapy, novel cellular therapies, cytokine release syndrome, cancer associated thrombosis, and moreComprises compact and updated disease-site chapters describing new standards of care and management considerations in bullet point format with key referencesHighlights important diagnostic tools that assist with conducting key differential diagnoses and unveiling answers to diagnostic dilemmasProvides updates of potential practice-changing clinical trials and paradigm shifting treatment considerations in each disease-based chapterPurchase includes digital access for use on most mobile devices or computers
Häftad, Engelska, 2025
1 013 kr
Tillfälligt slut
Handbook of Hematologic Malignancies 3rd Edition remains an indispensable resource for busy hematologists, hematologic oncologists, hematopathologists, oncology advanced practice providers, oncology nurses, and trainees. This significantly revised and completely updated edition is meticulously organized to provide concise, essential information on diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematologic malignancy. Each chapter features detailed figures that illustrate the hematopathologic characteristics of diseases, along with tables designed to simplify the review of differential diagnoses, prognostic scoring systems, molecular profiles, and therapeutic options.With over 35 new FDA-approved indications since the second edition—featuring groundbreaking advancements such as CAR-T therapy—this handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management. Purchase includes online access via most mobile devices or computers.Key Features:New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance.Entirely new board-style questions, enhancing critical thinking and knowledge application with every clinical chapter.Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading.Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas.Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology.